BRPI0807940B8 - usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido - Google Patents

usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido

Info

Publication number
BRPI0807940B8
BRPI0807940B8 BRPI0807940A BRPI0807940A BRPI0807940B8 BR PI0807940 B8 BRPI0807940 B8 BR PI0807940B8 BR PI0807940 A BRPI0807940 A BR PI0807940A BR PI0807940 A BRPI0807940 A BR PI0807940A BR PI0807940 B8 BRPI0807940 B8 BR PI0807940B8
Authority
BR
Brazil
Prior art keywords
acid
cancer
dihydropyrazol
hydroxybiphenyl
hydrazino
Prior art date
Application number
BRPI0807940A
Other languages
English (en)
Inventor
Lynn Erickson-Miller Connie
Original Assignee
Glaxo Group Ltd
Glaxosmithkline Llc
Novartis Ag
Novartis Pharma Ag
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0807940(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, Glaxosmithkline Llc, Novartis Ag, Novartis Pharma Ag, Smithkline Beecham Corp filed Critical Glaxo Group Ltd
Publication of BRPI0807940A2 publication Critical patent/BRPI0807940A2/pt
Publication of BRPI0807940B1 publication Critical patent/BRPI0807940B1/pt
Publication of BRPI0807940B8 publication Critical patent/BRPI0807940B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

agonista de receptor de tpo não peptídeo e seus usos na preparação de medicamentos para tratamento de cancêr e sídromes pré-cancerosas é inventado um processo de tratamento de câncer e síndromes pré-cancerosas em um mamífero, incluindo um humano, em sua necessidade que compreende a administração de uma quantidade terapeuticamente efetiva de um agonista de receptor tpq não-peptídeo a tal mamífero.
BRPI0807940A 2007-02-16 2008-02-15 usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido BRPI0807940B8 (pt)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US89023607P 2007-02-16 2007-02-16
US60/890.236 2007-02-16
US89255207P 2007-03-02 2007-03-02
US60/892.552 2007-03-02
US90820507P 2007-03-27 2007-03-27
US60/908.205 2007-03-27
US94934707P 2007-07-12 2007-07-12
US60/949.347 2007-07-12
US95228907P 2007-07-27 2007-07-27
US60/952.289 2007-07-27
US96919207P 2007-08-31 2007-08-31
US60/969.192 2007-08-31
US97721607P 2007-10-03 2007-10-03
US60/977.216 2007-10-03
PCT/US2008/054046 WO2008101141A2 (en) 2007-02-16 2008-02-15 Cancer treatment method

Publications (3)

Publication Number Publication Date
BRPI0807940A2 BRPI0807940A2 (pt) 2013-07-30
BRPI0807940B1 BRPI0807940B1 (pt) 2020-10-27
BRPI0807940B8 true BRPI0807940B8 (pt) 2021-05-25

Family

ID=39690807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807940A BRPI0807940B8 (pt) 2007-02-16 2008-02-15 usos de ácido 3´-{n´-[1-(3,4-dimetilfenil)-3-metil-5-oxo-1,5-diidropirazol-4-ilideno]-hidrazino}-2´-hidroxibifenil-3-carboxílico e/ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de câncer e de uma síndrome pré-cancerosa e composição farmacêutica que compreende dito ácido

Country Status (28)

Country Link
US (2) US20100075928A1 (pt)
EP (1) EP2124547B3 (pt)
JP (1) JP5511391B2 (pt)
KR (1) KR101447763B1 (pt)
CN (1) CN101662937B (pt)
AR (1) AR065348A1 (pt)
AU (1) AU2008216106C1 (pt)
BR (1) BRPI0807940B8 (pt)
CA (1) CA2678358C (pt)
CR (1) CR10997A (pt)
DK (1) DK2124547T6 (pt)
EA (1) EA017715B1 (pt)
ES (1) ES2675070T7 (pt)
FI (1) FI2124547T4 (pt)
HU (1) HUE038563T2 (pt)
IL (2) IL200319A (pt)
MA (1) MA31202B1 (pt)
MX (1) MX2009008822A (pt)
NZ (1) NZ579068A (pt)
PE (1) PE20081784A1 (pt)
PL (1) PL2124547T6 (pt)
PT (1) PT2124547T (pt)
SI (1) SI2124547T2 (pt)
TR (1) TR201809010T4 (pt)
TW (1) TW200906393A (pt)
UY (1) UY30915A1 (pt)
WO (1) WO2008101141A2 (pt)
ZA (1) ZA200905532B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
KR101530402B1 (ko) * 2007-10-09 2015-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (ｔｐｏｒａ)
EP2434894B1 (en) 2009-05-29 2016-08-31 Novartis AG Methods of administration of thrombopoietin agonist compounds
CA2808908A1 (en) * 2010-09-01 2012-03-08 Novartis Ag Combination of hdac inhibitors with thrombocytopenia drugs
WO2014150252A1 (en) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
SMT202300047T1 (it) * 2016-05-06 2023-03-17 Taris Biomedical Llc Metodo di trattamento del cancro uroteliale del tratto inferiore
RU2675695C1 (ru) * 2018-03-06 2018-12-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения рака предстательной железы высокого и очень высокого риска
CN121588107A (zh) * 2024-08-26 2026-03-03 李欣蕊 阿伐曲泊帕及其新治疗用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO1999011262A1 (en) 1997-09-02 1999-03-11 Roche Diagnostics Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia
KR20020069183A (ko) * 1999-07-26 2002-08-29 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 작동성을 나타내는 의약 조성물
DE60043156D1 (de) * 1999-11-10 2009-11-26 Biopheresis Technologies Inc Verfahren und system zur entfernung von zytokininhibitoren in patienten
EP1104674A1 (de) 1999-11-10 2001-06-06 Curacyte AG O,o'-Dihydroxyazofarbstoffe als Bestandteile von Arzneimitteln mit TPO-Agonistischer oder -Synergetischer Wirkung
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
TWI282785B (en) * 2000-05-30 2007-06-21 Chugai Pharmaceutical Co Ltd A compound having thrombopoietin-like activities
EP1284997B1 (en) * 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
MXPA03006510A (es) 2001-01-26 2003-10-15 Shionogi & Co Compuestos halogenados que muestran agonismo del receptor de trombopoyetina.
WO2002059099A1 (en) 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
CN101062053A (zh) * 2001-09-24 2007-10-31 托斯克公司 减低毒性的顺铂制剂及其使用方法
PT1466912E (pt) 2002-01-18 2013-06-28 Astellas Pharma Inc Derivado de 2-aciloaminotiazol ou seu sal
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2004029049A1 (ja) 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
EP1622609A4 (en) * 2003-04-29 2008-09-03 Smithkline Beecham Corp METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
DE602005024599D1 (de) * 2004-10-25 2010-12-16 Ligand Pharm Inc Verbindungen modulierende thrombopoietinaktivität und verfahren
CA2630234A1 (en) 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2008011666A (es) 2006-03-15 2008-10-17 Ligand Pharm Inc Sintesis de compuestos que modulan la actividad de la trombopoyetina.

Also Published As

Publication number Publication date
SI2124547T2 (sl) 2025-07-31
DK2124547T6 (da) 2025-09-01
ZA200905532B (en) 2010-04-28
IL200319A (en) 2015-05-31
BRPI0807940B1 (pt) 2020-10-27
CA2678358A1 (en) 2008-08-21
JP2010519221A (ja) 2010-06-03
US20100075928A1 (en) 2010-03-25
PL2124547T3 (pl) 2018-08-31
WO2008101141A3 (en) 2008-10-16
AU2008216106B2 (en) 2013-07-11
KR20090113330A (ko) 2009-10-29
US20090022814A1 (en) 2009-01-22
IL200319A0 (en) 2010-04-29
EP2124547B2 (en) 2025-04-16
EA200970776A1 (ru) 2010-02-26
EP2124547A4 (en) 2010-05-05
EA017715B1 (ru) 2013-02-28
TW200906393A (en) 2009-02-16
AU2008216106A1 (en) 2008-08-21
EP2124547A2 (en) 2009-12-02
PL2124547T5 (pl) 2025-08-04
EP2124547B1 (en) 2018-03-28
KR101447763B1 (ko) 2014-10-07
CN101662937A (zh) 2010-03-03
IL238394B (en) 2018-05-31
DK2124547T3 (en) 2018-07-16
PL2124547T6 (pl) 2026-06-01
IL238394A0 (en) 2015-06-30
PE20081784A1 (es) 2009-01-25
ES2675070T7 (en) 2025-08-06
FI2124547T4 (fi) 2025-07-29
CR10997A (es) 2009-10-16
CA2678358C (en) 2015-12-08
SI2124547T1 (en) 2018-08-31
TR201809010T4 (tr) 2018-07-23
MA31202B1 (fr) 2010-02-01
BRPI0807940A2 (pt) 2013-07-30
AU2008216106C1 (en) 2025-11-13
NZ579068A (en) 2012-05-25
DK2124547T4 (da) 2025-08-04
PT2124547T (pt) 2018-07-04
UY30915A1 (es) 2008-09-02
HUE038563T2 (hu) 2018-10-29
WO2008101141A2 (en) 2008-08-21
AR065348A1 (es) 2009-06-03
CN101662937B (zh) 2014-03-12
ES2675070T3 (es) 2018-07-06
EP2124547B3 (en) 2025-06-18
AU2008216106B9 (en) 2013-09-05
MX2009008822A (es) 2009-08-28
JP5511391B2 (ja) 2014-06-04

Similar Documents

Publication Publication Date Title
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
BRPI0708640A8 (pt) composição farmacêutica, e, métodos para tratar um paciente com dor de cabeça de enxaqueca, para tratar um paciente com dor e para tratar um paciente com enxaqueca
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
DE602007002154D1 (de) Analgesische Zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden Arzneimitteln und Opioiden
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
BRPI0720500A8 (pt) Preparação líquida transdérmica
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
NO20084542L (no) Farmasoytisk kombinasjon inneholdende 3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol og paracetamol
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
CL2008002096A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor vanilloide vr-1 y un antiinflamatorio no esteroidal o una sal o solvato de cualquiera o de ambos compuestos; composicion farmaceutica que comprende dicha combinacio; y su uso de la combinacion para tratar un trastorno mediado por ek receptor vainilloide vr1.
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
AR046951A1 (es) Moduladores de los receptores nucleares de hormonas esteroides triciclicos
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
WO2006081127A3 (en) Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
AR061477A1 (es) Metodos para utilizar un derivado de tiazol
BR112014004339A2 (pt) suspensão oral
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE LLC (US)

B25A Requested transfer of rights approved

Owner name: GLAXO GROUP LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF